Show simple item record

dc.contributor.authorMcCarthy, Alexandra
dc.contributor.authorReid, Carol
dc.contributor.authorStone, Leanne
dc.contributor.authorJones, Lee
dc.contributor.authorLangbecker, Danette
dc.contributor.authorJanda, Monkia
dc.contributor.authorLaing, Bobbi
dc.contributor.authorTenenbaum, Ron
dc.contributor.authorAtalag, Koray
dc.description.abstractBackground: Patient‐reported experience measures in cancer care ideally capture hospital performance in six domains advocated by the Institute of Medicine (IOM): Respect for patient needs and preferences Care coordination Information and education provision Physical support Emotional comfort Involvement of significant others. The Patient‐Reported Experience‐Cancer (PRE‐C) instrument was developed to capture these variables and inform responsive cancer service delivery. Aim: To determine PRE‐C reliability (α ≥ .7); to establish PRE‐C convergent and divergent validity. Method: The PRE‐C was developed with cancer patients and clinicians. Face and content validity were tested with 30 patients and 10 clinicians. Items were revised according to their feedback until a 28‐item questionnaire was ready for psychometric testing. A sample size of 280 was needed to determine reliability. Exploratory factor analysis (EFA) examined the PRE‐C's dimensionality. Maximum likelihood was used for extraction, with direct oblimin rotation examining correlation between constructs. Results: A total of 414 consecutively recruited ambulatory chemotherapy patients from a single tertiary hospital participated. EFA indicated that six of the 28 items were problematic – some fitted better in other domains and some did not measure as intended. Particularly problematic were items that explored respect for cultural preferences and the financial impacts of treatment. Removing these items and re‐running the EFA indicated reliability (α in the six domains ranging from .73 to .81). Discussion: The revised PRE‐C instrument reliably and accurately captured all IOM constructs. It is also important that the PRE‐C captures the financial and cultural experiences of cancer patients. To this end, we have revised the problematic items and are currently testing the PRE‐C with ambulatory patients in three large health services, anticipating N > 280 for a new EFA and >300 for subsequent confirmatory factor analysis. We are also preparing the instrument for digital embedment to enable routine, responsive data capture.
dc.relation.ispartofconferencenameCOSA's 46th Annual Scientific Meeting, Urological cancer; Age and gender in cancer practice; Digital health in cancer
dc.relation.ispartofconferencetitleASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
dc.relation.ispartoflocationAdelaide, South Australia
dc.subject.fieldofresearchOncology and Carcinogenesis
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.titleThe Patient-reported Experience (Cancer) Questionnaire: Development, validation, reliability testing ... and on to system-wide digitisation
dc.typeConference output
dc.type.descriptionE3 - Conferences (Extract Paper)
dcterms.bibliographicCitationMcCarthy, A; Reid, C; Stone, L; Jones, L; Langbecker, D; Janda, M; Laing, B; Tenenbaum, R; Atalag, K, The Patient-reported Experience (Cancer) Questionnaire: Development, validation, reliability testing ... and on to system-wide digitisation, Asia-Pacific Journal of Clinical Oncology, 2019, 15, pp. 74-75
gro.hasfulltextNo Full Text
gro.griffith.authorLaing, Bobbi
gro.griffith.authorReid, Carol L.
gro.griffith.authorScuffham, Paul A.

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

  • Conference outputs
    Contains papers delivered by Griffith authors at national and international conferences.

Show simple item record